BirchBioMed Inc.

BirchBioMed is a clinical-stage biopharmaceutical company and a University of British Columbia (UBC) spinoff. The company focuses on developing regenerative treatments for organ fibrosis, topical scarring, and autoimmune diseases, leveraging exclusive worldwide licenses for medical therapeutic technologies from UBC. Their pipeline includes advanced therapies such as FS2 (kynurenic acid), which targets scarring on a molecular level, and AI-001 for autoimmune conditions. The company is actively engaged in clinical trials and has recently achieved significant regulatory milestones, including Health Canada approval for its topical scar cream and FDA Orphan Drug Designation for FS2 in the treatment of Idiopathic Pulmonary Fibrosis (IPF).